MA32705B1 - Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation - Google Patents

Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation

Info

Publication number
MA32705B1
MA32705B1 MA33762A MA33762A MA32705B1 MA 32705 B1 MA32705 B1 MA 32705B1 MA 33762 A MA33762 A MA 33762A MA 33762 A MA33762 A MA 33762A MA 32705 B1 MA32705 B1 MA 32705B1
Authority
MA
Morocco
Prior art keywords
beta
compounds
secretase
disorders
useful
Prior art date
Application number
MA33762A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Marian C Bryan
Ryan White
Albert Amegadzie
Jian J Chen
Alan C Cheng
Thomas Dineen
Oleg Epstein
Vijay Keshav Gore
Zihao Hua
Jason B Human
Hongbing Huang
Charles Kreiman
Daniel La
Qingyian Liu
Vu Van Ma
Isaac Marx
Vinod F Patel
Wenyuan Qian
Matthew Weiss
Chester C Yuan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA32705B1 publication Critical patent/MA32705B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA33762A 2008-09-11 2011-04-11 Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation MA32705B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9608208P 2008-09-11 2008-09-11
PCT/US2009/056748 WO2010030954A1 (en) 2008-09-11 2009-09-11 Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use

Publications (1)

Publication Number Publication Date
MA32705B1 true MA32705B1 (fr) 2011-10-02

Family

ID=41319591

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33762A MA32705B1 (fr) 2008-09-11 2011-04-11 Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation

Country Status (21)

Country Link
US (1) US8426447B2 (cg-RX-API-DMAC7.html)
EP (1) EP2328903B1 (cg-RX-API-DMAC7.html)
JP (1) JP5579720B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110073511A (cg-RX-API-DMAC7.html)
CN (1) CN102209721A (cg-RX-API-DMAC7.html)
AU (1) AU2009291602B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0918449A2 (cg-RX-API-DMAC7.html)
CA (1) CA2736130C (cg-RX-API-DMAC7.html)
CL (1) CL2011000516A1 (cg-RX-API-DMAC7.html)
CO (1) CO6362014A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110134A (cg-RX-API-DMAC7.html)
EA (1) EA201100461A1 (cg-RX-API-DMAC7.html)
ES (1) ES2459195T3 (cg-RX-API-DMAC7.html)
IL (1) IL211440A0 (cg-RX-API-DMAC7.html)
MA (1) MA32705B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011002705A (cg-RX-API-DMAC7.html)
MY (1) MY148558A (cg-RX-API-DMAC7.html)
PE (1) PE20110805A1 (cg-RX-API-DMAC7.html)
TW (1) TWI385175B (cg-RX-API-DMAC7.html)
WO (1) WO2010030954A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201102674B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2753730C (en) 2009-03-13 2020-12-22 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2539322B1 (en) 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
JP5584352B2 (ja) * 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
US8883782B2 (en) * 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
WO2011130741A1 (en) * 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US8921363B2 (en) * 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
JP2013536233A (ja) 2010-08-23 2013-09-19 アムジエン・インコーポレーテツド グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物
TW201229048A (en) * 2010-11-22 2012-07-16 Idemitsu Kosan Co Oxygenated fused ring derivative and organic electroluminescence element containing the same
TW201307357A (zh) * 2010-11-22 2013-02-16 Array Biopharma Inc 治療神經退化性疾病之化合物
WO2012071279A1 (en) * 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
EP2675810A1 (en) 2011-02-15 2013-12-25 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CA2837797A1 (en) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag [1,3]oxazines
JP2014524472A (ja) 2011-08-22 2014-09-22 メルク・シャープ・アンド・ドーム・コーポレーション Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
EP2650284A1 (en) * 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
AU2013267555A1 (en) * 2012-05-30 2014-12-04 Comentis, Inc. Chromane compounds
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US10548882B2 (en) 2012-06-21 2020-02-04 Astrazeneca Ab Camsylate salt
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
SG10202100916PA (en) 2015-02-02 2021-02-25 Valo Early Discovery Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
DE102023106829A1 (de) 2023-03-19 2024-09-19 List Technology Ag Verfahren und Vorrichtung zur Behandlung eines Ausgangsproduktes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683718A (en) * 1952-01-11 1954-07-13 Searle & Co Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione
US3185696A (en) * 1959-03-12 1965-05-25 Jack M Tien 3', 6'-diaminofluoran derivatives of gamma-lactam
FR2576178B1 (fr) 1985-01-24 1987-04-17 Furodet Philippe Procede de fabrication pour un enfumoir a chargement par-dessous
DE3601492A1 (de) 1986-01-20 1987-07-23 Vacuumschmelze Gmbh Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
SI9300303A (en) 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
KR100839284B1 (ko) 1998-09-24 2008-06-17 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
CA2410680A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US7196163B2 (en) 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
BR0210721A (pt) 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
BR0211118A (pt) 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA04000328A (es) 2001-07-10 2004-07-23 Pharmacia & Upjohn Comapny Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
US20030109559A1 (en) 2001-07-11 2003-06-12 Andrea Gailunas N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
EP1432674A2 (en) 2001-10-04 2004-06-30 Elan Pharmaceuticals, Inc. Hydroxypropylamines
BR0213138A (pt) 2001-10-05 2004-08-24 Elan Pharm Inc Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto
BR0213743A (pt) 2001-10-29 2004-12-21 Upjohn Co Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição
KR20050044407A (ko) 2001-11-08 2005-05-12 엘란 파마슈티칼스, 인크. N,n'-치환-1,3-디아미노-2-히드록시프로판 유도체
AR037460A1 (es) 2001-11-30 2004-11-10 Smithkline Beecham Plc Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion
AU2002360508A1 (en) 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
CA2472617A1 (en) 2002-01-04 2003-07-17 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
WO2003062209A2 (en) 2002-01-17 2003-07-31 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
WO2003106405A1 (en) 2002-06-01 2003-12-24 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
CA2489988A1 (en) 2002-06-20 2003-12-31 Michael R. Reeder Process for preparing 5-(1,3-oxazol-2-yl) benzoic acid derivatives
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
WO2004043916A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
GB0228410D0 (en) 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
AU2004204692B2 (en) 2003-01-07 2009-07-09 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease
GB0305918D0 (en) 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
WO2004080459A1 (en) 2003-03-14 2004-09-23 Merck Sharp & Dohme Limited Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease
WO2004094384A2 (en) 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease
WO2004094413A1 (en) 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
EP1641748B1 (en) 2003-06-30 2013-08-28 Merck Sharp & Dohme Corp. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
EP1643986A4 (en) 2003-07-01 2009-04-08 Merck & Co Inc PHENYL ACARBOXYLATE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005058311A1 (en) 2003-12-15 2005-06-30 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
CA2561267A1 (en) 2004-03-30 2005-10-20 Merck & Co., Inc. 2-aminothiazole compounds useful as aspartyl protease inhibitors
TW200602045A (en) 2004-06-16 2006-01-16 Wyeth Corp Amino-5, 5-diphenylimidazolone derivatives for the inhibition of β-secretase
WO2006041404A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-compounds and uses thereof
AU2006205127A1 (en) 2005-01-14 2006-07-20 Wyeth Amino-imidazolones for the inhibition of beta-secretase
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
MX2007016186A (es) 2005-06-14 2008-03-07 Schering Corp Preparacion y uso de inhibidores de proteasas.
ATE490251T1 (de) * 2005-06-16 2010-12-15 Janssen Pharmaceutica Nv Tricyclische opioidmodulatoren
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
WO2007009014A2 (en) * 2005-07-13 2007-01-18 Raviv Laor Personal topical disinfectant device
WO2007011833A2 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
EP2256107A1 (en) 2005-09-26 2010-12-01 Wyeth LLC Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE)
JP5281794B2 (ja) 2005-10-25 2013-09-04 塩野義製薬株式会社 アミノジヒドロチアジン誘導体
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
TW200808751A (en) 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
JP2009539983A (ja) 2006-06-12 2009-11-19 シェーリング コーポレイション 複素環式アスパルチルプロテアーゼ阻害薬
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
ATE538651T1 (de) 2006-10-30 2012-01-15 Merck Sharp & Dohme Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
NZ578260A (en) 2007-02-02 2012-02-24 Hoffmann La Roche Novel 2-aminooxazolines as taar1 ligands for cns disorders
CL2008000791A1 (es) 2007-03-23 2008-05-30 Wyeth Corp Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
TW200902503A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
MY160690A (en) 2008-01-18 2017-03-15 Eisai R&D Man Co Ltd Condensed aminodihydrothiazine derivative
BRPI0907563A2 (pt) 2008-02-18 2015-08-04 Hoffmann La Roche Derivados de 4,5-di-hidro-xazol-2-il amina
TW201004957A (en) 2008-04-22 2010-02-01 Schering Corp Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
WO2010010014A1 (en) 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
KR20110048491A (ko) * 2008-07-28 2011-05-11 에자이 알앤드디 매니지먼트 가부시키가이샤 스피로아미노디하이드로티아진 유도체들

Also Published As

Publication number Publication date
TW201022280A (en) 2010-06-16
AU2009291602A1 (en) 2010-03-18
JP2012502112A (ja) 2012-01-26
TWI385175B (zh) 2013-02-11
IL211440A0 (en) 2011-05-31
CO6362014A2 (es) 2012-01-20
ES2459195T3 (es) 2014-05-08
CR20110134A (es) 2011-08-04
US8426447B2 (en) 2013-04-23
MY148558A (en) 2013-04-30
US20100087429A1 (en) 2010-04-08
BRPI0918449A2 (pt) 2019-09-24
CA2736130C (en) 2014-01-14
EA201100461A1 (ru) 2011-10-31
WO2010030954A1 (en) 2010-03-18
PE20110805A1 (es) 2011-11-09
ZA201102674B (en) 2011-12-28
JP5579720B2 (ja) 2014-08-27
EP2328903B1 (en) 2014-03-05
CL2011000516A1 (es) 2011-08-26
EP2328903A1 (en) 2011-06-08
CN102209721A (zh) 2011-10-05
KR20110073511A (ko) 2011-06-29
AU2009291602B2 (en) 2013-02-14
MX2011002705A (es) 2011-09-09
CA2736130A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA29807B1 (fr) Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques.
MX2009012608A (es) Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
MA34922B1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
MA30981B1 (fr) Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments
MA27132A1 (fr) Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA32506B1 (fr) Nouveaux composes
MA29809B1 (fr) N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA32374B1 (fr) Composes comprenant un groupe cyclobutoxy
MA29989B1 (fr) Tetrahydro-pyridoazepine-8-ones et composes apparentes, pour le traitement de la schizophrenie
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
DE602004010314D1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von degs-inhibitoren
MA29793B1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques.